Search research articles
Contact Us
Filters
Showing results (51-60 of 119) with videos related to
Page
of 12
Sort By:
Cancer Immunology, Immunotherapy : CII
|
August 5, 2022
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
Shumin Yuan, Ling Peng, Yuqing Liu, et al.
Leukemia & Lymphoma
|
May 3, 2008
Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma
Brian G Till, Theodore A Gooley, Nathan Crawford, et al.
British Journal of Haematology
|
June 23, 2020
Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade
Victor A Chow, Paul S Martin, Stephen D Smith, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 10, 2018
Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma
Stephen D Smith, Shruti Gandhy, Ajay K Gopal, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 12, 2010
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation
Scott E James, Philip D Greenberg, Michael C Jensen, et al.
Genomics
|
February 13, 2001
Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q)
F Lai, L A Godley, J Joslin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 15, 2022
Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
M Lia Palomba, Brian G Till, Steven I Park, et al.
Plos One
|
December 21, 2013
Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma
Lihua E Budde, Carolina Berger, Yukang Lin, et al.
Blood Advances
|
January 10, 2024
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic
Rahul Banerjee, Christina Poh, Alexandre V Hirayama, et al.
British Journal of Haematology
|
October 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma
Ryan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 119) with videos related to
Sort By:
Page
of 12
Cancer Immunology, Immunotherapy : CII
|
August 5, 2022
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
Shumin Yuan, Ling Peng, Yuqing Liu, et al.
Leukemia & Lymphoma
|
May 3, 2008
Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma
Brian G Till, Theodore A Gooley, Nathan Crawford, et al.
British Journal of Haematology
|
June 23, 2020
Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade
Victor A Chow, Paul S Martin, Stephen D Smith, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 10, 2018
Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma
Stephen D Smith, Shruti Gandhy, Ajay K Gopal, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 12, 2010
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation
Scott E James, Philip D Greenberg, Michael C Jensen, et al.
Genomics
|
February 13, 2001
Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q)
F Lai, L A Godley, J Joslin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 15, 2022
Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
M Lia Palomba, Brian G Till, Steven I Park, et al.
Plos One
|
December 21, 2013
Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma
Lihua E Budde, Carolina Berger, Yukang Lin, et al.
Blood Advances
|
January 10, 2024
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic
Rahul Banerjee, Christina Poh, Alexandre V Hirayama, et al.
British Journal of Haematology
|
October 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma
Ryan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Page
of 12